Livongo
Hemant Taneja, managing director of General Catalyst, talks about what tech can learn from health and vice versa.
2020 is shaping up to be a record-breaking year for digital health startups.
More people experienced high blood pressure in response to the COVID-19 pandemic compared to before, according to new research from chronic care management company Livongo.
After news broke about the $18.5 million deal all eyes in the digital health world have been on Livongo and Teladoc.
The MobiHealthNews team breaks down the week's big digital health news: Teladoc's proposed $18 billion acquisition of Livongo.
Also: Dexcom continues to make strides, while iRhythm Technologies takes a hit in Q2.
Each Livongo share will be converted Teladoc stock at a 0.5920 exchange rate, plus an additional $11.44 in cash per stock.
A new study conducted by the digital chronic disease management company highlighted engagement behaviors associated with stronger outcomes over 12 months.
Large health tech customers are more cautious and overwhelmed than ever, which means that many younger digital health startups will face an uphill battle selling their products in the months to come.
Also Fitbit struggles as it waits to be acquired by Google, and Livongo sees strong growth.